3) Brain-computer interface applications in neurodegeneration
4) Cognitive applications and tests in neurodegeneration
5) Computerized tomography in assessment of neurodegeneration
6) Frailty indexed systems in neurodegeneration
7) Magnetic resonance imaging (MRI) in assessment of neurodegeneration
8) Medical decision support systems in neurodegeneration
9) SPECT perfusion imaging in assessment of neurodegeneration
10) The use of cerebrospinal fluid in the diagnosis of neurodegeneration
11) Animal-assisted therapy in neurodegeneration
12) Cholinesterase inhibitors and NMDA receptor antagonists in neurodegeneration
13) Cognitive Impairment and Rehabilitation
14) Depression and Psychotic symptoms in neurodegeneration
15) Environmental enrichment for multisensory Stimulation in neurodegeneration
16) Immunotherapy in neurodegeneration
17) Mediterranean diet in neurodegeneration
18) Nanotechnological applications in diagnosis and treatment of neurodegeneration
19) Natural products as promising drug candidates for neurodegeneration
20) Sleep in neurodegeneration
21) Health Economics and management of neurodegeneration
22) Health tourism in neurodegeneration
23) Transcranial direct current stimulation in ASD and AD
Ethical, Legal and Social Implications
24) Biobanks, Big Data and Data Sharing in ASD and AD
25) Failed clinical trials in ASD and AD
26) Gene Editing, CRISPR and human enhancements in ASD and AD
27) Health Economics and Management of ASD and AD
28) Health Tourism in ASD and AD
29) Implementation of precision Medicine in ASD and AD
30) Next-Generation Ethics and IRB in ASD and AD
31) Preparing professionals for ASD and AD
Dr Ghulam Md Ashraf is an associate professor at King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia. His PhD is in biochemistry from Aligarh Muslim University in India. He has more than 250 publications on neuroscience and understanding anti-diabetic drugs' molecular and behavioral mechanisms in various dementia conditions. He is also involved in many research projects at the King Abdulaziz University and in the editorial capacity in many reputed journals, like PLOS one, Scientific Reports, Frontiers in Neuroscience, Current Proteins and Peptides, Current Drug Metabolism, Current Gene Therapy, and Journal of Proteomics.
Dr Athanasios Alexiou is a faculty member at the Novel Global Community Education Foundation in Australia. His PhD from the Ionian University is in bioinformatics algorithms and mathematical modelling in biology and his Postdoc on neuroinformatics applications. His main research field is biomedical informatics and bioethics, specializing in medical decision support systems, biomarkers modelling, and computational neuroscience. He serves as an associate editor in high impact journals with almost 100 publications and several research projects in neuroscience.
This book talks about the multidimensional biological etiology of Alzheimer’s disease and autism spectrum disorder which leads to distinctive ways of perception, thinking and learning in affected individuals. It provides a deeper emphasis on the need for early diagnosis, continuous assessment of patients and the proper educational methods and environment required towards enabling people affected with these disorders capable of evolving and learning.
This book explores alternative solutions for autism spectrum disorder based on the theory of brain plasticity, the relationship between the gut microbiota and the central nervous system along with genetic factors and toxic metal exposures which are responsible for the oxidative damage resulting in a decreased ability of the patients to use objects or response to auditory stimuli. It also identifies and provides the latest research towards dealing with memory loss, which is the first sign of cognitive impairment followed by behavioral disturbances. These symptoms are associated with a rigorous neuronal decline and the appearance of two brain lesions, senile plaques and neurofibrillary tangles, which are mainly composed of Aβ and hyper phosphorylated tau protein respectively. This book also provides the latest research towards reducing autism disorder severity such as targeting the disease with symptomatic treatments such as cholinesterase inhibitors, NMDA receptor antagonist, β-secretase and γ-secretase inhibitors, α-secretase stimulators, tau inhibitors, immunotherapy, nutraceuticals, and nano drugs.
This book will not only be a good resource for professors and lecturers teaching in the area of neuroscience, medicine, biochemistry, neuroinformatics, and nanotechnology, etc. but also for professionals working in the field of occupational therapy and geriatric clinics and rehabilitation.